Sepiapterin is a PAH activator that reduces blood Phe levels by increasing the intracellular concentrations of tetrahydrobiopterin and protecting against PAH enzyme misfolding.

The study results “highlight how even well-intentioned efforts to save patients’ time may face barriers,” the researchers wrote.

Lonapegsomatropin is a pegylated prodrug of the human growth hormone, somatropin, administered as a subcutaneous injection once-weekly.

Following publication of advisories, reports of local anesthetic poisoning decreased, but reports of lidocaine poisoning and mortality increased.

The Food and Drug Administration (FDA) has extended the review period for elinzanetant, an investigational hormone-free therapy for the treatment of moderate to severe vasomotor symptoms (VMS) due to ...

AOMs linked to significant weight regain at eight weeks after drug discontinuation compared with control group.

US Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. signed off on the recommendation from an expert panel that recommended removing the mercury-based preservative from all influenza ...

HealthDay News — Patients with irritable bowel syndrome (IBS) with self-perceived gluten sensitivity react similarly to wheat, gluten, and sham challenges, according to a study published online July ...

HealthDay News — Reusable feminine hygiene products often contain per- and polyfluoroalkyl substances (PFAS), according to a study published online July 22 in Environmental Science & Technology ...

HealthDay News — The US Food and Drug Administration has announced a plan to revoke 52 food standards after concluding they ...

The single-arm, open-label DR-OVP-002 study is currently evaluating Ovaprene in sexually active women aged 18 to 40 years who ...

AD109 is an investigational oral therapy that combines aroxybutynin, an antimuscarinic, with atomoxetine, a selective norepinephrine reuptake inhibitor.